Considerations for Moderna&#x27;s move to get an EUA for the COVID-19 vaccine in young kids

January 14th 2025

PDUFA date set for neffy 1 mg for children who weigh 33 lbs or more

The lead clinical trial investigator for a phase 3 study of crinecerfont in pediatric CAH patients breaks down the December 2024 FDA approval.

January 13th 2025

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg).

January 10th 2025

2024’s critical needle-free approvals for pediatric anaphylaxis, influenza

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

December 26th 2024

FDA approves concizumab-mtci prophylaxis for hemophilia A and B

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.

FDA approves first generic GLP-1 injection for type 2 diabetes in patients 10 years and up

The indication is for patients 12 years and older hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

Patrick Campbell

Kyriakie Sarafoglou, MD, discusses crinecerfont FDA approval for congenital adrenal hyperplasia

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Related Content

January 14th 2025

PDUFA date set for neffy 1 mg for children who weigh 33 lbs or more

The lead clinical trial investigator for a phase 3 study of crinecerfont in pediatric CAH patients breaks down the December 2024 FDA approval.

January 13th 2025

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg).

January 10th 2025

2024’s critical needle-free approvals for pediatric anaphylaxis, influenza

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

December 26th 2024

FDA approves concizumab-mtci prophylaxis for hemophilia A and B

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.

FDA approves first generic GLP-1 injection for type 2 diabetes in patients 10 years and up

The indication is for patients 12 years and older hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

Patrick Campbell